Following a 1-for-52 reverse stock split of common shares traded on the Toronto Stock Exchange, Sophiris Bio Inc., of La Jolla, Calif., slashed its planned public offering price from $13 per share to $5 per share, while increasing the number of shares offered to maintain a target of $65 million in gross proceeds.